Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Short-term Investments (2020 - 2026)

C4 Therapeutics has reported Short-term Investments over the past 7 years, most recently at $174.4 million for Q1 2026.

  • For Q1 2026, Short-term Investments rose 6.47% year-over-year to $174.4 million; the TTM value through Mar 2026 reached $174.4 million, up 6.47%, while the annual FY2025 figure was $173.9 million, 8.17% down from the prior year.
  • Short-term Investments for Q1 2026 was $174.4 million at C4 Therapeutics, roughly flat from $173.9 million in the prior quarter.
  • Over five years, Short-term Investments peaked at $264.1 million in Q3 2022 and troughed at $127.1 million in Q4 2023.
  • A 5-year average of $191.7 million and a median of $189.4 million in 2024 define the central range for Short-term Investments.
  • Biggest five-year swings in Short-term Investments: plummeted 48.42% in 2023 and later soared 49.03% in 2024.
  • Year by year, Short-term Investments stood at $246.4 million in 2022, then plummeted by 48.42% to $127.1 million in 2023, then surged by 49.03% to $189.4 million in 2024, then fell by 8.17% to $173.9 million in 2025, then grew by 0.27% to $174.4 million in 2026.
  • Business Quant data shows Short-term Investments for CCCC at $174.4 million in Q1 2026, $173.9 million in Q4 2025, and $133.1 million in Q3 2025.